Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis (SAR)

Next Previous
Trial Profile

A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis (SAR)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone/olopatadine (Primary) ; Mometasone; Olopatadine
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd

Most Recent Events

  • 14 Nov 2019 Results assessing efficacy and safety of olopatadine-mometasone for the treatment of seasonal allergic rhinitis, published in the Annals of Allergy, Asthma and Immunology.
  • 25 Feb 2019 Results of a pooled analysis of nasal symptoms and TEAEs from NCT02318303, NCT02631551, NCT02870205 trials, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 25 Feb 2019 Results of a pooled analysis of Onset of Action and Ocular Symptom from NCT02318303, NCT02631551, NCT02870205 trials, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top